In one of the final steps before a marketing authorization decision by the European Medicines Agency, it recommended ...

GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for ...

GSK (GSK) announced the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has recommended expanding ...

In another press release, GSK announced that the CHMP has recommended expanded use of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary advanced or recurrent ...

GSK's cancer drug Jemperli cleared an important hurdle ahead of potentially expanding its European Union marketing permission, in a boost to the pharmaceutical giant's oncology pipeline.

London: GSK plc has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for ...

智通财经APP获悉，GSK (GSK.US) 日前宣布，美国FDA已授予其PD-1抑制剂Jemperli (dostarlimab)用于治疗局部晚期错配修复缺陷 (dMMR)/高微卫星不稳定性 (MSI-H)直肠癌的突破性疗法认定 (BTD)。

GSK’sGSK-0.41%decrease; red down pointing triangle cancer drug Jemperli cleared an important hurdle ahead of potentially receiving marketing permission from the European Medicines Agency.

GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for Jemperli for the treatment of patients with locally advanced mismatch ...

GSK's cancer drug Jemperli cleared an important hurdle ahead of potentially receiving marketing permission from the European Medicines Agency. The British pharmaceutical giant said Monday that the ...